These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 31642193)
1. Adeno-Associated Viral Vectors for Homology-Directed Generation of CAR-T Cells. Moço PD; Aharony N; Kamen A Biotechnol J; 2020 Jan; 15(1):e1900286. PubMed ID: 31642193 [TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Mollanoori H; Shahraki H; Rahmati Y; Teimourian S Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related]
4. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Morgan MA; Büning H; Sauer M; Schambach A Front Immunol; 2020; 11():1965. PubMed ID: 32903482 [TBL] [Abstract][Full Text] [Related]
5. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. Liu J; Zhou G; Zhang L; Zhao Q Front Immunol; 2019; 10():456. PubMed ID: 30941126 [TBL] [Abstract][Full Text] [Related]
6. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy. Ding R; Chao CC; Gao Q Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989 [TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy. Liu X; Zhao Y Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200 [TBL] [Abstract][Full Text] [Related]
8. Engineering strategies to safely drive CAR T-cells into the future. Rossi M; Breman E Front Immunol; 2024; 15():1411393. PubMed ID: 38962002 [TBL] [Abstract][Full Text] [Related]
9. AAVS1 site-specific integration of the CAR gene into human primary T cells using a linear closed-ended AAV-based DNA vector. Chen W; Tan L; Zhou Q; Li W; Li T; Zhang C; Wu J J Gene Med; 2020 Apr; 22(4):e3157. PubMed ID: 31901177 [TBL] [Abstract][Full Text] [Related]
10. Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors. Mo F; Mamonkin M Methods Mol Biol; 2020; 2086():119-130. PubMed ID: 31707671 [TBL] [Abstract][Full Text] [Related]
11. Optimized Production of Lentiviral Vectors for CAR-T Cell. Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668 [TBL] [Abstract][Full Text] [Related]
12. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells. MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835 [TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors. Morgan MA; Schambach A Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435 [TBL] [Abstract][Full Text] [Related]
14. Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy. Mirzaei HR; Pourghadamyari H; Rahmati M; Mohammadi A; Nahand JS; Rezaei A; Mirzaei H; Hadjati J Cancer Lett; 2018 Jun; 423():95-104. PubMed ID: 29544719 [TBL] [Abstract][Full Text] [Related]
15. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects. Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708 [TBL] [Abstract][Full Text] [Related]
16. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells. Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119 [TBL] [Abstract][Full Text] [Related]
17. Bacteria-free minicircle DNA system to generate integration-free CAR-T cells. Cheng C; Tang N; Li J; Cao S; Zhang T; Wei X; Wang H J Med Genet; 2019 Jan; 56(1):10-17. PubMed ID: 30030293 [TBL] [Abstract][Full Text] [Related]
18. Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors. Ochi T; Maruta M; Hirano N Methods Mol Biol; 2019; 2048():27-39. PubMed ID: 31396926 [TBL] [Abstract][Full Text] [Related]
19. Generation of CAR-T Cells for Cancer Immunotherapy. Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215 [TBL] [Abstract][Full Text] [Related]
20. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]